Per the deal terms, Sarepta will acquire exclusive rights to Arrowhead’s seven pipeline programs, which include four in active clinical development and the remaining three in preclinical ...

Shares of Sarepta Therapeutics (SRPT) have gained 0.2% over the past four weeks to close the last trading session at $130.50, but there could still be a solid upside left in the stock if short ...

The surge in the stock price can be attributed to the encouraging sales performance of Duchenne muscular dystrophy (DMD) gene therapy Elevidys. Elevidys – A Key Driver of Sarepta’s Top line ...

Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...

The company’s fiscal Q4 update centered primarily on the large collaboration deal announced with Sarepta (SRPT) (SPRT) and implications for its own strategy going forward, the analyst tells ...

Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...

Sarepta Therapeutics Stock Performance Shares of NASDAQ SRPT opened at $133.34 on Friday. Sarepta Therapeutics, Inc. has a 52-week low of $78.67 and a 52-week high of $173.25. The stock has a ...

NexImmune has higher earnings, but lower revenue than Sarepta Therapeutics. NexImmune is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price target lowered by Piper Sandler from $200.00 to $182.00 in a report issued on Wednesday,Benzinga reports.The brokerage currently ...